Summary
=======

Patients with confirmed COVID-19 had pulmonary embolism diagnosed in 37% of CTPA examinations with D-dimer levels associated with the presence of pulmonary embolism and the degree of pulmonary artery obstruction.

Key results:
============

1.  ■ CTPA was positive for pulmonary embolism in 37% of COVID-19 patients.

2.  ■ D-dimer levels directly correlate with the presence and extent of pulmonary embolism as indicated by the Mastora index and can be used to risk stratify patients for pulmonary embolism workup.

Introduction {#s1}
============

The novel 2019 coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 began in December 2019 and by March 2020 reached pandemic levels ([@r1]). Current guidelines through the American College of Radiology and the Centers for Disease Control do not support routine screening for COVID-19 with imaging; rather nasopharyngeal or oropharyngeal swab for viral RNA testing is the recommended confirmatory test. This perspective is based on literature that demonstrates that chest computed tomography (CT) may be falsely negative early in the disease, with chest CT reserved for evaluation of complications ([@r2], [@r3]).

Hypercoagulability has been reported in patients who have COVID-19 (COVID+), with increased mortality associated with elevated serum thrombogenic proteins such as D-dimer ([@r4]). In fact, patients with severe COVID-19 who were empirically treated with low-molecular weight heparin (LMWH) had a lower 28-day mortality compared with similarly-ill patients that were not treated with LMWH ([@r5], [@r6]). This raises the question of whether thrombotic and embolic events worsen the patient's clinical status.

In particular, there is a heightened awareness of pulmonary embolism in COVID+ patients, which would diminish the already compromised pulmonary function and capacity. Currently, a few case series ([@r7]-[@r11]), clinical reports ([@r12], [@r13]), and recent radiology research report letters in European cohorts have been published on pulmonary embolism, which is diagnosed using CT pulmonary angiography (CTPA) ([@r14], [@r15]). Many acutely-ill and hospitalized COVID+ patients have multi-organ failure and possibly acute kidney injury ([@r16]), and decisions as to whether CTPA is performed take into consideration both the potential risk of nephrotoxicity from intravenous contrast administration and the benefit of diagnosing pulmonary embolism.

Therefore, an understanding of the frequency of pulmonary embolism and the relationship between D-dimer levels and the degree of pulmonary artery obstruction may aid in the diagnosis and management of this disease in COVID+ patients. Our objective was to determine the prevalence of pulmonary embolism on CTPA studies in a United States (US) cohort of COVID+ patients and identify clinical features associated with a positive CTPA exam, pulmonary artery obstruction severity, and outcomes.

Materials and Methods {#s2}
=====================

The study was approved for an exemption by the institutional review board (IRB). Written informed consent was waived by the IRB. The study was a Health Insurance Portability and Accountability Act-compliant retrospective review of pertinent clinical and imaging data on consecutive CTPA studies at NYU Langone Health and affiliated hospitals. Two cohorts are detailed below.

General Methods
---------------

This is a single-institution retrospective study in which the radiology information system was queried (Primordial, Nuance Communications, Inc., Burlington, MA) by a radiology resident (MK) using search terms of "pulmonary embolism" to identify CTPA examinations performed between March 13, 2020 and April 5, 2020. The electronic medical record (EMR) (Epic, Verona, WI) for these patients was reviewed to identify those who had COVID-19 infection confirmed by coronavirus polymerase chain reaction (PCR) of nasopharyngeal or oropharyngeal swab samples. Only the patients who tested positive for COVID-19 on PCR were included in the study sample. All patients included in the study were 18 years of age or older. Those with technically inadequate CTs by review of radiology reports ([Figure 1](#fig1){ref-type="fig"}) were excluded. This resulted in a cohort that comprised 62 COVID+ patients who had CTPAs with pulmonary embolism (CTPA positive) and without pulmonary embolism (CTPA negative).

![CTPA cases in patients with COVID-19 (COVID+) population. CTPA: Computed tomography pulmonary angiography; COVID: Coronavirus disease.](ryct.2020200308.fig1){#fig1}

In the COVID+ confirmed patient cohort, gender, age, CTPA indication, and comorbidity parameters of pre-existing hypertension, diabetes mellitus, chronic obstructive pulmonary disease, coronary artery disease, and smoking history were recorded by review of medical records. Pertinent laboratory values were collected, including D-dimer at admission and on the date closest to the CTPA examination, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), coagulation markers (prothrombin time-PT, international normalized ratio-INR, and partial thromboplastin time-PTT), and platelet count. D-dimer was ordered at physician discretion. The time from symptom onset to admission/emergency room visit, need for ventilator support, and clinical outcome were documented for each patient. The time between the D-dimer closest to CTPA study and the imaging exam was calculated, in addition to any change in D-dimer between admission and that closest to the CTPA. The use of any prophylactic or therapeutic anticoagulation was collected and the date of initiation was recorded if initiated during the current hospitalization. Prophylactic anticoagulation was typically either subcutaneous enoxaparin (40-60 mg according to BMI) or subcutaneous heparin. Therapeutic anticoagulation was typically subcutaneous enoxaparin (1 mg/kg) twice daily or intravenous heparin. Clinical outcomes at time of medical record review were identified: 1-discharged, 2-improved as indicated by decreasing oxygen requirement, 3- not improved or clinically worsening as evidenced by increasing oxygen requirement, or 4-expired. Any venous ultrasound examinations to evaluate for deep venous thrombosis (DVT) in addition to echocardiograms performed within 48 hours of the CTPA to assess for right heart strain and pulmonary hypertension were identified. The presence of right heart strain on a preexisting echocardiogram was assessed for the COVID+ CTPA-positive patients. The presence of other thrombotic events was recorded for the same hospitalization or outpatient encounter: ischemic stroke, intracerebral venous and arterial thrombosis, abdominal thrombosis, and peripheral vascular arterial thrombosis. Additionally, the clinical setting in which the CTPA was ordered was documented.

A second cohort of the same number of patients who had CTPA examinations just preceding March 1, 2020 (the date of the first documented case of COVID-19 infection in New York) was identified retrospectively and sequentially (pre-COVID) for comparison of CTPA positivity rate with our COVID+ cohort. The same search term of "pulmonary embolism" was used, and all included patients were 18 years and older. Of the 62 patients, 1 CTPA was excluded given study was reported as non-diagnostic. Gender, age, comorbidities, patient setting of CTPA, clinical indication for CPTA, DVT on ultrasound, and clinical outcomes were collected.

Image data
----------

Chest CTPA protocol at our institution entailed intravenous administration of 300 mg/mL of iodinated contrast at 3 to 5 mL per second with timing optimized for the pulmonary artery using bolus tracking and automatic triggering. Imaging was performed after a small suspended breath hold. Detector-row configuration of multidetector CT scanners ranged from 64 to 128 x 0.6. Dual-energy CT technique entailed dual source configuration using 100 kVp (A tube)/150 kVp (B tube) and ref mAs of 130 (A tube)/ 100 (B tube), and single energy CTPA used either 100 or 120 kVp with ref mAs of 147 and 130 mAs, respectively. Gantry rotation times were 0.28-0.5 seconds. Reconstructions included 1 mm and 2 mm axial soft tissue sections and coronal and sagittal reformats.

Two board-certified thoracic radiologists with 16 (WM) and 22 years (JPK) experience in thoracic imaging independently reviewed the anonymized CTPA positive examinations on clinical PACS monitors. They graded the image quality of the CTPA exam was scored ordinally as 1-diagnostic, optimal; 2- diagnostic-adequate, 3-diagnostic limited and 4-non-diagnostic. Degree of pulmonary obstruction was assessed using Mastora obstruction scoring system ([@r17]), grading each of the following vessels for the degree of obstruction (1: \<25%; 2: 25--49%; 3: 50--74%; 4: 75--99%; 5: 100%) of: main pulmonary artery (MPA), right pulmonary artery (RPA), left pulmonary artery (LPA), both interlobar arteries, lobar, and segmental pulmonary arteries. Discrepancies were resolved by consensus between the two radiologists. For each patient, a total score was generated by summing the obstruction score of every vessel evaluated, and an obstruction ratio for all arteries was generated by dividing the total score for each patient by the maximum possible score of 155 (ObstTotRatio). An obstruction ratio for central arteries only (MPA, RPA, LPA, interlobar and lobar arteries) (ObstCenRatio) was achieved by dividing the sum of the scores for these vessels by the maximum possible score of 55. For all COVID+ patients, the extent of pulmonary opacities attributed to COVID-19 was assessed by the radiology readers using an adaptation of a scoring system ([@r18]); each of 6 lobes (left upper lobe, lingula, left lower lobe and the right upper, middle, and right lower lobes) were scored in terms of the percentage of the lobe involved by COVID-19-related lung abnormalities (0= 0%, 1 = \<25%, 2= 25 to \<50%, 3 =50 to \<75%, 4 =75% to 100%). The proportion of the parenchyma involved by abnormalities (COVIDLungRatio) was achieved by dividing the sum of all scores by a maximal possible score of 24. The presence or absence of consolidation was recorded and confirmed by consensus.

The readers assessed for the presence of a focally dilated subsegmental vessel (vascular enlargement) within an area of ground-glass or consolidative opacity in a lung region supplied by pulmonary embolism. This finding was defined as an area in which a vessel became focally dilated, in comparison to the area just proximal to the region and in comparison to other vessels at a similar branching level in the pulmonary arterial tree. Vascular enlargement was assessed also in ground-glass areas in the parenchyma not involved in pulmonary embolism. The presence of right heart strain on CT, as indicated by the right ventricular (RV)/left ventricular (LV) ratio \> 1, contrast reflux into the inferior vena cava to the hepatic veins and coronary sinus, and degree of septal bowing toward the LV, was recorded. For the RV/LV ratio, the maximal dimensions of the RV and LV chambers were obtained by measuring perpendicularly from inner aspect of free wall to inner aspect of the interventricular septum ([@r19]). Consensus was obtained for discrepancies between the two readers. If either the CTPA or the echocardiogram demonstrated right heart strain, the patient was considered as positive for right heart strain.

Statistical Methods
-------------------

Patients that were CTPA positive and negative were compared in terms binary factors using a Fisher exact test and in terms of ordinal and numeric factors using an exact Mann-Whitney test. For each binary feature including the presence of comorbidities, smoking history, mechanical ventilatory support, and DVT, the Fisher exact test compared the proportions within the CTPA positive and negative groups. For each numeric feature (age, laboratory values, time from symptoms to admission/emergency room visit, COVIDLungRatio), the mean, standard deviation (SD), median and inter-quartile range (IQR) for CTPA positive and CTPA negative patients were compared using the exact Mann-Whitney test performed. A Fisher exact test was used to identify differences in CTPA and DVT positivity rate between the COVID+ cohort and cohort prior to COVID-19. The cohorts were also compared in terms of clinical features with Fisher exact and Mann-Whitney text.

Association of factors and patient outcomes were calculated. For numeric outcomes of RV/LV ratio (as an indicator of right heart strain), ObstCenRatio, and ObstTotRatio with numeric clinical features were performed using Spearman correlation. For binary factors, an exact Mann-Whitney test was used to compare those with and without the factor for numeric outcomes.

For significant numeric predictors of CTPA positivity, the Youden index from a receiver operator characteristic (ROC) analysis was used to identify a threshold that was optimal for the detection of CTA positive patients with sensitivity and specificity calculated. Additional thresholds were investigated for significant factors, such as D-dimer based on clinical knowledge of \> 500 and \> 2000 ng/mL DDU. A *P* value of \<.05 was considered statistically significant. Statistical analysis was performed using Statistical Analysis Software (SAS) 9.4 software (SAS Institute, Cary, NC).

Results {#s3}
=======

The COVID+ cohort was composed of 62 patients with 40 men and 22 women, mean age of 57.8 +/- (SD) 13.9 years (range of 28-89 years) with men having mean age of 55.5 +/- (SD) 13.6 years and women mean 61.9 +/- (SD) 13.8 years ([Table 1](#tbl1){ref-type="table"}). In the COVID+ cohort, 37.1% (23/62) CTPA studies were positive for pulmonary embolism ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}). Diabetes, hypertension, and smoking history were identified in 30.6% (19/62), 35.5% (22/62), and 34.6% (18/52) of patients ([Table 1](#tbl1){ref-type="table"}), respectively. In terms of the CTPA positive and CTPA negative COVID+ cohorts ([Table 1](#tbl1){ref-type="table"}), patients with diabetes had a lower proportion on CTPA positive exams (*P*=.025). No significant difference between gender, the other investigated comorbidities, DVT on ultrasound, and smoking history, and clinical outcome between CTPA positive and CTPA negative COVID+ patients was identified ([Table 1](#tbl1){ref-type="table"}). The first provided clinical indication for the CTPA study order or documented indication in the medical record for the 62 COVID+ patients was: hypoxia in 17 (27%), respiratory distress in 16 (26%), elevated D-dimer in 14 (23%), tachycardia in 7 (11%), chest pain in 4 (6.5%), extremity swelling in 1 (1.6%), and 3 (4.8%) had an indication not specified above. In the COVID+ cohort, CTPA examinations were ordered on patients in the emergency department in 31/62 (50.0%), as an inpatient in 27/62 (43.5%), and while in the intensive care unit (ICU) in 4/62 (6.5%).

###### 

Clinical Characteristics of COVID-19 patients who had diagnostic chest CTPA and differences in clinical features between positive and negative CTPA patients.

![](ryct.2020200308.tbl1)

![A COVID+ patient with bilateral pulmonary emboli had D dimer of \> 10,000 four days after admission. *A,* Axial CTPA image shows bilateral pulmonary emboli in the left main pulmonary artery and right upper lobe proximal segmental vessels. *B,* On an image in the lower thorax, the right ventricle is larger than the left ventricle indicating right heart strain. *C,* Bilateral parenchymal consolidative and ground glass opacities are present with a peripheral orientation in the right upper lobe and left lower lobe superior segments. Central and peripheral ground glass in the left upper lobe is present. ObstTotRatio was 0.568.](ryct.2020200308.fig2){#fig2}

![A COVID+ patient with bilateral pulmonary emboli had D dimer of \> 10,000. *A,* Coronal CTPA image identifies bilateral pulmonary emboli that involve the left main pulmonary artery, distal right main pulmonary artery, right upper lobe pulmonary artery, and proximal segmental vessels. *B,* On an axial CTPA image, there is an embolus present in the left main and right upper lobe pulmonary arteries extending into the bilateral anterior segmental artery. Dilated vessels are present centrally. The ObstTotRatio was 0.674. *C,* A ground glass opacity in present in the right upper lobe centrally with a reversed halo appearance, peripheral dense area, and central ground glass opacity attributed to lung involvement from COVID-19. *D,* Axial image through the lung base demonstrate basilar consolidation compatible with COVID-19.](ryct.2020200308.fig3){#fig3}

In the COVID+ cohort, 25 of 62 patients (40%) had been receiving prophylactic dose anticoagulation at the time of CTPA for a mean of 4.6 +/- (SD) 3.1 days of prophylaxis, and pulmonary embolism was diagnosed in 52% (13/25). Five additional patients of 62 (8.1%) had been receiving therapeutic dose anticoagulation at the time of the CTPA, secondary to underlying hypercoagulable or pro-embolic co-morbid conditions including prior diagnosis of atrial fibrillation, past history of portal vein thrombosis, past history of pulmonary embolism (2 patients), and current deep venous thrombosis; 20% (1/5) of these were CTPA positive. CTPA was diagnosed in 31% (10/32) of patients who had not been receiving anticoagulation.

In the CTPA positive subgroup, 8.7% (2/23) patients ([Table 1](#tbl1){ref-type="table"}) expired, while in the CTPA negative subgroup 12.8% (5/39) expired. CTPA positive patients clinically worsened in 26.1% (6/23) of cases in terms of increasing degree of supplemental oxygen requirement, compared to 12.8% (5/39) in the CTPA negative group ([Table 1](#tbl1){ref-type="table"}). The review by the two readers did not yield additional studies deemed non-diagnostic, beyond those that had been initially excluded.

In the COVID+ patients, 15 of 62 patients (24%) underwent venous ultrasound, and DVT was present in 53% (8/15) of the studies ([Figure 4](#fig4){ref-type="fig"}). Considering all COVID+ patients with thromboembolic diagnoses (CTPA positive and/or DVT), 24 of 62 (38.7%) were positive, and 38 of 62 lacked thromboembolic diagnoses (61.3%).

![COVID+ patients with deep venous ultrasound of the lower extremity and deep venous thrombosis. COVID+: Coronavirus disease; CTPA: Computed tomography pulmonary angiography; DVT+: Had DVT; DVT- Did not have DVT](ryct.2020200308.fig4){#fig4}

One CTPA-positive patient of the 62 (1.6%) COVID+ cohort had a lower-extremity arterial thrombus demonstrated on arterial imaging during the current hospitalization. No additional thrombotic events were identified within the remainder of the COVID+ cohort by review of the medical record including any neurologic, abdominopelvic, and extremity imaging.

The pre-COVID cohort comprised 62 patients with 22 men and 40 women (mean age 58.0 +/- (SD) 19.2 years, range 21-94) with men having a mean age of 59.8 +/- (SD) 18.0 years and women 57.1 +/- (SD) 20.0 years. Within the pre-COVID cohort, 41.8% (26/62) had hypertension; 27.4% (17/62) had diabetes; 17.7% (11/62) had coronary artery disease; 11.3% (7/62) had COPD; and 41.8% (23/55 patients with known smoking status) had a reported smoking history (Supplemental Table 1). Of these features, a greater percentage of patients were female *P*=.002) and had coronary artery disease (*P*=.016) in the pre-COVID patients than the COVID+ cohort (see Supplemental Table 1). Within the pre-COVID cohort, CTPA studies were ordered in an outpatient setting in 9/62 (21.4%), emergency department in 42/62 (67.7%), an inpatient setting in 11/62 (17.7%) patients. No patients were in the intensive care unit at the time of CTPA. The indication listed first in the CTPA order or in the medical record for the 62 patients were: respiratory distress in 23 (37%), tachycardia in 13 (21%), elevated D-Dimer in 11 (18%), lower extremity swelling in 4 (6.5%), hypoxia in 3 (4.8%), chest pain in 3 (4.8%), and non-specified indication in 3 patients (4.8%). Of the nine positive CTPA examinations in this cohort, 66.7% (6/9) were men; 55.6% (5/9) had hypertension; 33.3% (3/9) had diabetes; 11.1% (1/9) had coronary artery disease; 22.2% (2/9) had COPD; and 71.4% (5/7 patients with known smoking status) had a reported smoking history. Two patients from the pre-COVID cohort expired, including one of the CTPA positive patients. Lower-extremity ultrasound examinations were performed in 21 (34%) of 62 pre-COVID patients. Six of these 21 patients (29%) demonstrated DVT on ultrasound; 4 of 21 patients (19%) were detected in CTPA positive patients, and 2 of 21 patients (10%) were identified in CTPA negative patients. The 29% (6/21) with DVT in the pre-COVID cohort did not differ (*P*=.169) from the 53% (8/15) of COVID+ patients who had DVT. This pre-COVID cohort had a 14.5% (9/62) positive CTPA rate, which was lower than that of the COVID+ cohort (37.1%) (*P*=.007). When accounting for all patients with pulmonary embolism and/or DVT, 17.7% (11/62) were positive in this pre-COVID cohort, lower than that of the COVID+ cohort (38.7%) (*P=*.016).

In terms of the hematologic and coagulation laboratory values within the COVID+ cohort, only D-dimer on the date closest to the CTA demonstrated a statistically significant difference between CTPA positive and CTPA negative subgroups with mean 6432.3 ng/mL D-dimer units (DDU) +/- (SD) 3675.9 ng/mL for CTPA positive (range 368 to \> 10,000 ng/mL DDU) and 1774.6 +/- (SD) 3003.8 ng/mL DDU for CTPA negative patients (range 100 ng/mL DDU to 13109 ng/mL DDU) (*P\<*.001) ([Table 2](#tbl2){ref-type="table"})*.* The one patient with a negative CTPA who was diagnosed with a DVT had a D-dimer value of \> 10,000 ng/mL DDU. The time between D-dimer and CTPA was mean 0.10 days +/- (SD) 1.08 days, median 0, range 3 days prior to 5 days after CTPA. Other laboratory values and the duration of symptoms before presentation to hospital/emergency room did not differ statistically, including the change in D-dimer between admission and the date closest to CTPA. Time between the two D-dimers for CTPA positive patients was 4.8 days +/- (SD) 3.3 (range 1-12) days and for CTPA negative patients 4.1 +/- (SD) 3.3 (range 1-11) days ([Table 2](#tbl2){ref-type="table"}). Within the pre-COVID cohort, D-dimer was ordered on 32/62 51.6% patients with mean 1095.2 +/- (SD) 1122.4 ng/mL DDU and was lower than in the COVID+ patients (*P*=.008). The pre-COVID patients who were CTPA positive and had a D-dimer test had mean value of 1293.5 +/- (SD) 1372.8 ng/mL DDU, significantly lower than observed in the COVID+ CTPA-positive cohort (*P*=.013).

###### 

Comparison of patients with negative and positive CTPA studies in terms of quantitative laboratory values, clinical features and imaging features.

![](ryct.2020200308.tbl2)

Additionally, the COVIDLungRatio, reflecting degree of lung parenchyma affected by opacities, was not statistically different between CTPA positive and CTPA negative subgroups with mean 0.56 +/- (SD) 0.27 for CTPA positive patients and 0.66 +/- (SD) 0.17 for CTPA negative patients (*P*\>.05) ([Table 1](#tbl1){ref-type="table"}). Consolidation was present in 55 of 62 (88.8%) of patients, 23 of whom were CTPA positive patients and 32 of whom were CTPA negative patients. Only 1 of 62 (1.6%) patients had a dilated vessel in an area of consolidation and ground-glass opacity (vascular enlargement), observed in a CTPA positive patient with a segmental pulmonary embolism affecting the region ([Figure 3](#fig3){ref-type="fig"}). No vessel dilation within a COVID-19 lesion was identified in areas unaffected by pulmonary embolism.

ROC analysis on the significant factor D-dimer (at the date closest to the CTPA) identified that a value greater than 1394 ng/mL DDU predicted CTPA positivity with an area under the curve (AUC) =0.857, with 94.5% (21/22) sensitivity and 71.4% (25/35) specificity. Use of a lower D-dimer threshold value of \>500 ng/mL DDU resulted in a sensitivity of 95.5% (21/22) and a specificity of 42.9% (15/35) for a CTPA positive result. For a D-dimer threshold level greater than 2000 ng/mL DDU, CTPA positive results would be indicated with a sensitivity of 77.3% (17/22) and a specificity of 82.9% (29/35). When grouping the one patient with DVT with those who were CTPA positive, the threshold of 1394 ng/mL DDU predicted DVT and/or pulmonary embolism with AUC=0.880 and achieved a 95.7% (22/23) sensitivity and 73.5% (25/34) specificity. The sensitivities using thresholds of \>500 ng/mL DDU and \> 2000 was 95.7% (22/23) and 78.3% (18/23), respectively, while specificities were 44.1% (15/34) and 85.3% (29/34), respectively.

Pulmonary Embolism Severity
---------------------------

For the CTPA positive patients, 10 of 23 (43.5%) patients had evidence of right heart strain on either echocardiogram or CTPA ([Figure 2](#fig2){ref-type="fig"}), with 1 of 10 (10%) with right heart strain (moderate) on echocardiography only, 1 of 10 (10%) had right heart strain on both echocardiogram (mild) and CTPA, and 8 of 10 (80%) had right heart strain only on CTPA. Of the 8 patients that had CTPA right heart strain, 5 did not undergo echocardiogram. No significant difference in clinical characteristics including laboratory values and clinical outcome was delineated based on the presence or absence of right heart strain (*P*\>.05) (Supplemental Table 2). Two of 10 patients (20.0%) who were CTPA positive and had right heart strain expired, whereas none of the CTPA positive patients who did not have right heart strain expired (Supplemental Table 2). None of the CTPA positive patients with right heart strain on echocardiogram and/or CTPA had a preexisting echocardiogram within one year prior to the COVID+ hospitalization.

ObstCenRatio, ObstTotRatio, and the RV/LV ratio did not differ significantly between the patient gender, preexisting conditions, and clinical outcome for each metric of pulmonary embolism severity (*P*\>.05)(Supplemental Table 3). The ObstCenRatio was mean 0.15 +/- (SD) 0.20. The ObstTotRatio was mean 0.20 +/- (SD) 0.21. The mean RV/LV ratio was 1.20 +/- (SD) 0.55 ([Figure 3](#fig3){ref-type="fig"}) for CTPA positive patients; the mean was 1.55 +/- (SD) 0.74 for those assessed by the radiologist consensus to have RV strain and was 0.95 +/- (SD) +/- 0.13 for those without RV strain.

There was a statistically significant and positive correlation between both ObstCenRatio (*P*=.007), and ObstTotRatio (*P*=.002) with D-dimer levels ([Table 3](#tbl3){ref-type="table"}). The ESR laboratory value negatively correlated with the ObstCenRatio (*P*=.002) and the ObstTotRatio (*P*=.011). The COVIDLungRatio negatively correlated with RV/LV ratio (*P*\<.02) but no significant correlation with the ObstCenRatio and the ObstTotRatio was identified. Duration of symptoms prior to hospital presentation positively correlated with (*P=*.033) RV/LV ratio ([Table 3](#tbl3){ref-type="table"}).

###### 

Correlation of laboratory values, imaging measures, and duration of symptoms prior to hospitalization with indicators of pulmonary embolism severity.

![](ryct.2020200308.tbl3)

Discussion {#s4}
==========

In this study of a US cohort of COVID+ patients who had CTPA, 37.1% of exams were positive for pulmonary embolism. D-dimer significantly differed between patients who had positive CTPA and those with negative CTPA exams. Additionally, D-dimer levels correlated with the degree of pulmonary artery obstruction as measured by the Mastora grading system (ObstCenRatio and ObstTotRatio).

The high prevalence of positive CTPA exams in COVID+ patients in our study supported the growing knowledge pertaining to the relationship between COVID-19 and hypercoagulable states including disseminated intravascular coagulation (DIC) ([@r6]) ([@r20]). The association of COVID-19 with thromboembolic disease has been indicated by an ultrasound study by Cui et al, which reported peripheral venous thromboembolism in 25% of patients with severe COVID-19 ([@r21]). Pulmonary embolism in COVID+ patients has been described only recently, beginning with single case and small-series reports ([@r7]-[@r9]) ([@r10], [@r11]). Our study findings supported two recently published radiology research letters describing 23% ([@r14]) and 30% ([@r16]) of CTPA exams to be positive in European COVID+ cohorts. The high rate of pulmonary embolism in our study occurred despite 40% of the patients receiving prophylactic anticoagulation, 52% who had positive CTPAs. Additionally, a brief clinical report by Llitjos et al further reinforced the association of COVID-19 and pulmonary embolism, with a high rate of peripheral venous thrombosis in 56% and pulmonary embolism in 23% of their COVID+ ICU patients, despite prophylaxis and therapeutic anticoagulation; their rate of pulmonary embolism was potentially underestimated, given that positive peripheral thrombosis patients may not necessarily have had CTPA ([@r12]). The 37.1% with pulmonary embolism in our COVID+ cohort was higher than the 10% rate ([@r22]) reported in the general population and 14.5% (9/62) in our comparison group imaged just prior to the first case of COVID-19 reported in the New York City Area. When including patients who were either CTPA positive and/or had DVT, 38.7% of our COVID+ group were CTPA positive. Additionally, it is acknowledged that patient selection and the exam interpreter expertise can influence the proportion of positive CTPA exams, as all of the COVID+ patients were hospitalized or in the emergency room at time of exam ([@r23]). Despite this, the heightened risk of pulmonary embolism in COVID-19 was supported by our elevated percentage of positive CTPA exams in COVID+ patients, compared to the 22.7% and 30% rates reported in cohorts composed of only acutely ill intensive care unit patients prior to COVID-19 ([@r24], [@r25]). Also, a majority of the emergency department CTPA exams are interpreted by thoracic radiologists at our institution, and thus, the effect of interpreter expertise is minimized (([@r23])).

Recent literature in COVID-19 has reported thrombosis secondary to the COVID-associated vascular injury ([@r26], [@r27]). It is difficult to reliably distinguish between thrombus formation and embolism on CTPA. We did not specifically evaluate whether the central CTPA intravascular defects extended to distal subsegmental vessels. Our COVID-19 cohort had a higher rate of DVT (53%) compared to 29% in our pre-COVID cohort, suggesting a thromboembolic component for the intravascular defects on CTPA, though this difference was not statistically significant, possibly due to small numbers. Given the association of COVID-19 with a hypercoagulable state, prophylactic anticoagulation has been studied and shown to decrease mortality ([@r6]), and the role of empiric prophylactic and therapeutic anticoagulation needs elucidation ([@r28]).

Some imaging studies reported vascular enlargement or dilatation in areas of lung opacity as a feature of COVID-19 ([@r29], [@r30]), which we observed in only one patient in our study who had pulmonary embolism, who had vessel dilation in an area of consolidation and ground-glass opacity with a "reverse halo" sign. The significance and cause of the finding of vessel enlargement in COVID-19 is therefore not clarified by our study. Vascular enlargement in lung opacities in COVID-19 has been increasingly reported on chest CT; some have defined vessel enlargement as a subsegmental vessel greater than 3 mm in diameter. It has been proposed that vessel enlargement relates to hyperemia and inflammation from infection or other vascular disease, although the etiology is unclear at this time ([@r31]). The lack of vascular enlargement reported in this study may well relate to the severity of diseased lung parenchyma, given that 0.56 and 0.66 of the lungs were involved by opacities in our CTPA positive and CTPA negative subsets, respectively. The finding has mainly been reported in chest CT in scenarios in which CT may have been performed as a method of COVID-19 diagnosis and thus potentially may be seen in milder and earlier presentations of pulmonary COVID-19 than in our cohort ([@r30]-[@r32]). A higher threshold for this finding, given the use of visual qualitative assessment rather than a quantitative size definition, may account for small amount of this finding reported.

Our results indicate that D-dimer, a fibrin degradation product, was associated with a higher prevalence of thromboembolic events and correlated with the degree of pulmonary artery obstruction as shown by the Mastora score, which has been used as an indicator of pulmonary embolism severity. D-dimer was significantly elevated in CTPA patients with pulmonary embolism, with a mean of 6432.3 ng/mL, compared to 1774.6 ng/mL in CTPA negative patients (*P*\<.001) and 1293.5 ng/mL DDU for those patients who were pre-COVID CTPA positive (*P*=.013). The mean D-dimer for the COVID+ cohort of 3572.3 ng/mL DDU was significantly higher than the mean D-dimer values of 1095.2 ng/mL DDU for the entire pre-COVID cohort (*P*=.008). The particularly high D-dimer levels in the COVID+ cohort may relate to the pro-inflammatory and hypercoagulable COVID+ state. D-dimer positively correlated with degree of pulmonary embolism obstruction as measured by ObstCenRatio and the ObstTotRatio, for the central and for both central and segmental pulmonary arteries, respectively. This correlation between D-dimer and pulmonary embolism is well buttressed by the existing literature ([@r33], [@r34]), although a number of causes for D-dimer elevation exist that we did not specifically analyze, including DIC from multiple etiologies, pregnancy, age, and cancer ([@r35]). However, our investigation raises the possibility of risk stratification according to D-dimer value for pulmonary embolism in COVID+ patients. A 500 ng/mL value is used as a threshold for D-dimer positivity in the general population ([@r33]). Our study demonstrated that a D-dimer value of 1394 ng/mL provided a sensitivity of 95% and a specificity of 71% for pulmonary embolism in our COVID+ cohort. When including the patient who had a DVT but a negative CTPA, the rate of thromboembolic disease increased to 38.7%. This may aid in identifying those patients with higher likelihood of pulmonary embolism and determining those who should be considered for CTPA, particularly given the need to minimize in hospital transmission of COVID-19 to other patients and staff.

Most of the other demographic, comorbid, laboratory, clinical, and imaging features did not differ significantly between the CTPA positive and negative subgroups. A history of diabetes was the only comorbidity that was significantly less frequently observed in the CTPA positive cohort, which may possibly be attributed to our relatively small sample size (only 3/23 patients with pulmonary embolism had diabetes). Additionally, the inflammatory marker ESR was inversely associated with the severity of pulmonary embolism as evidenced by ObstCenRatio and the ObstTotRatio. This may reflect our small sample size of 10 CTPA positive patients who had an ESR value. The proportion of abnormal lung parenchyma thought to be related to COVID (COVIDLungRatio) was inversely proportional to the presence of RV/LV ratio. An explanation for this association is not clear, and this finding may also be related to our small numbers. In terms of outcome, we did not identify a significant mortality difference between the CTPA positive and negative cohorts (8.7% versus 12.8%), which could reflect diagnosis and treatment of pulmonary embolism although is unclear given our small numbers. Compared to our pre-COVID cohort, COVID+ patients had a significantly higher fraction of men, which may result from men associated with worse prognosis and higher mortality. It is unclear why a lower proportion of coronary artery disease was seen in the COVID+ patients compared to the pre-COVID group. Possibly more pre-COVID patients who had coronary artery disease and chest pain may have undergone CTPA due to overlapping clinical presentations than patients in the COVID+ cohort.

There has been association of better outcomes of COVID+ patients treated with anticoagulation prophylaxis, such as low molecular weight heparin in sepsis induced coagulopathy and high D-dimers ([@r5], [@r28]). Awareness and identification of thromboembolic complications such as pulmonary embolism may aid in improving outcomes as diagnosed patients would be treated with anticoagulation.

As discussed, a major limitation of our study is the relatively small sample size. Also, COVID-19 in our cohort may have raised the threshold of health care professionals for ordering CTPAs, given concerns pertaining to the contamination of CT scanners and in-hospital transmission of disease, thus elevating the proportion of positive examinations. Conversely, critically-ill patients with pulmonary embolism may not have had CTPA due to their being ventilated and unstable clinical status. Furthermore, many patients with ultrasound-confirmed peripheral venous thrombosis may not have had CTPA. Also, we compared the CTPA positivity rate in COVID+ patients to that of a cohort prior to COVID-19 that was not specifically matched for demographic, comorbid, or laboratory data, including D-dimer values and serves as a basis for future investigations. This may entail correlation of D-dimer levels with pulmonary artery severity and comparison between these two cohorts. We cannot exclude the possibility that undetected COVID-19 was present in the geographic population before March 1, 2020. Despite these aspects, an increased rate of thromboembolic events, pulmonary embolism, and derangements in coagulation factors in COVID+ patients has been supported by recent literature and is higher than that reported in ICU patient cohorts ([@r12]-[@r15], [@r24]). Additionally, due to the retrospective design of our study, many patients lacked laboratory testing of coagulation and inflammatory markers during their workup, limiting our evaluation of values such as for fibrinogen, ferritin, and ESR; echocardiography; and understanding for ordering CTPA. Also, echocardiography is subject to observer variation ([@r36]). Another limitation is that we cannot ascertain whether right heart strain was acute or preceded the current clinical presentation. However, none of the investigated COVID+ CTPA-positive patients with right heart strain on CTPA or echocardiogram had echocardiograms in the year prior to the COVID+ hospitalization, so right heart strain chronicity cannot be reliably ascertained. Some of the patients' final clinical outcomes have not been established due to the short time frame between pulmonary embolism CTPA and data collection for this study. Nasopharyngeal PCR testing was the gold standard for determining COVID-19 infection; however, the test is not 100% sensitive ([@r37]). Thus, the true rate of pulmonary embolism may be higher in our network as there may have been patients with positive CTPA studies who were not identified to be COVID+. Additionally, as mentioned previously, chest CT was not performed routinely for initial diagnosis of COVID-19, and our patient population may have reflected those with more severe lung involvement. Thus, we were unable to address vascular enlargement proposed by other investigators ([@r29], [@r30]) as a sign in early COVID-19 infection. Future investigation with a larger cohort may elucidate influencing factors for pulmonary embolism.

In conclusion, 37.1% of the CTPA examinations were positive for pulmonary embolism in a US cohort of COVID+ patients. We have demonstrated that D-dimer levels differed significantly between CTPA positive and negative studies and correlated with the severity of pulmonary artery obstruction. This supports the growing understanding that hypercoagulable events are elevated in COVID+ patients, and these patients are at increased risk for pulmonary embolism. Pulmonary embolism should remain a primary differential consideration for all COVID+ patients exhibiting acute or subacute respiratory distress. D-dimer levels can potentially be used to risk stratify patients in terms of suspicion for pulmonary embolism and severity.
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